Krka DDLTS:0HLK 84 Gross Margin % is 60.45% as of Mar. 2026, which is 6% above its 10-year median of 57.11. GuruFocus rates LTS:0HLK with a GF Score™ of 84/100 and a GF Value™ of €41.97 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 938 Drug Manufacturers companies, Krka DD ranks better than 66.1% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Krka DD's Gross Profit for the
three
months ended in Mar. 2026 was €342 Mil. Krka DD's Revenue for the
three
months ended in Mar. 2026 was €566 Mil. Therefore, Krka DD's Gross Margin % for the quarter that ended in Mar. 2026 was 60.45%.
The historical rank and industry rank for Krka DD's Gross Margin % or its related term are showing as below:
LTS:0HLK'
s Gross Margin % Range Over the Past 10 Years
Min: 53.37 Med: 57.11 Max: 59.37
Current: 58.55
During the past 13 years, the highestGross Margin % of Krka DD was 59.37%. The lowest was 53.37%. And the median was 57.11%.
LTS:0HLK's Gross Margin % is ranked better than 66.1% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs LTS:0HLK: 58.55
Krka DD had a gross margin of 60.45% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Krka DD was -0.30% per year.
Krka DD (LTS:0HLK) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Krka DD had a gross margin of 60.45% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Krka DD Gross Margin % Related Terms
Krka DD Gross Margin % Historical Data
* Premium members only.
The historical data trend for Krka DD's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HLK vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Krka DD's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Krka DD (LTS:0HLK) has a Gross Margin % of 60.45% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Krka DD and its competitors. This is near median its historical median of 57.11. Over the past decade, Krka DD's Gross Margin % has ranged from 53.37 to 59.37. According to the industry distribution chart, Krka DD ranks #318 out of 938 companies in the Drug Manufacturers industry, placing it in the top 33.9%.
Is Krka DD's Gross Margin % too high?
Krka DD's current Gross Margin % of 60.45% is near median its 10-year median of 57.11. Over the past 10 years, this metric has ranged from a low of 53.37 to a high of 59.37. The Drug Manufacturers industry median Gross Margin % is 48.54. Krka DD's value of 60.45% is 24.5% above this industry median. Based on the distribution chart, Krka DD ranks #318 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Krka DD has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #318 out of 938 companies for Gross Margin %. This puts Krka DD in the upper half of its industry. The industry median Gross Margin % is 48.54. Krka DD's value of 60.45% is 24.5% above this benchmark. Historically, Krka DD's own Gross Margin % has ranged from 53.37 to 59.37 over the past decade. While the company's 10-year median is 57.11 vs. the industry median of 48.54, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current Gross Margin % of 60.45% is 24.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current Gross Margin % is 60.45%, which is near median its own 10-year median of 57.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (LTS:0HLK) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.97, compared to a current price of €64.80 — trading 54.4% above its estimated fair value. The current Gross Margin % is 60.45%, which is near median its 10-year median of 57.11 and 24.5% above the Drug Manufacturers industry median of 48.54. Krka DD's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Krka DD (LTS:0HLK), the current Gross Margin % is 60.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (LTS:0HLK) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €64.80 is trading 54.4% above its estimated GF Value™ of €41.97.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for LTS:0HLK:
Gross Margin %: 60.45% (near median its 10-year median of 57.11)
GF Value™: €41.97 vs. price of €64.80 (54.4% above fair value)
Industry Position: 24.5% above the Drug Manufacturers median (#318 of 938)
No single metric tells the full story. See the LTS:0HLK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
84GF Score
Get the complete analysis for LTS:0HLK
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HLK has been successfully added to your 
